ABI-274

• CAT Number: I021212
• CAS Number: 1253697-93-6
• Molecular Formula: C20H20N2O4
• Molecular Weight: 352.39
• Purity: 98%
• Synonyms: ABI-274; ABI 274; ABI274
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: [2-(4-methylphenyl)-1H-imidazol-5-yl]-(3,4,5-trimethoxyphenyl)methanone
• InChI: InChI=1S/C20H20N2O4/c1-12-5-7-13(8-6-12)20-21-11-15(22-20)18(23)14-9-16(24-2)19(26-4)17(10-14)25-3/h5-11H,1-4H3,(H,21,22)
• InChIKey: NQHVDNDKHQBFKP-UHFFFAOYSA-N
• SMILES: CC1=CC=C(C=C1)C2=NC=C(N2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC

ABI-274（Cat No.:I021212）is a selective small-molecule inhibitor of the Bruton’s tyrosine kinase (BTK), a crucial enzyme in B-cell receptor signaling, which plays a key role in the immune response. By inhibiting BTK, ABI-274 blocks B-cell activation and the downstream signaling that contributes to autoimmune diseases and certain cancers, such as B-cell malignancies. It has shown promise in preclinical studies for the treatment of conditions like rheumatoid arthritis, lupus, and various types of lymphoma. ABI-274’s targeted action on BTK makes it a potential therapeutic agent for immune-related disorders and B-cell-driven cancers.